Drugs / Zr89-trastuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01420146 | Aug 2011 → Sep 2015 | HER2 positive breast carcinoma | Jules Bordet Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zr89-trastuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01420146 ↗ |
| Modality | Monoclonal antibody | “labelled monoclonal antibody” NCT01420146 ↗ |